Cibc World Market Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 14.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 576,304 shares of the company’s stock after purchasing an additional 70,817 shares during the period. Cibc World Market Inc.’s holdings in Johnson & Johnson were worth $119,266,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Blueline Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $25,000. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $26,000. Cresta Advisors Ltd. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. DecisionPoint Financial LLC raised its position in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the period. Finally, Family CFO Inc bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $31,000. Institutional investors own 69.55% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on JNJ shares. Johnson Rice raised shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Morgan Stanley set a $283.00 target price on Johnson & Johnson in a report on Wednesday, April 15th. Sanford C. Bernstein raised their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Stifel Nicolaus increased their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Finally, Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, April 24th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $253.04.
Key Stories Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Johnson & Johnson reported encouraging Phase 2 results for nipocalimab in lupus, meeting the primary endpoint and showing sustained disease activity reduction through 52 weeks. Article Title
- Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s ability to reduce autoantibodies and showed stronger response rates in patients with higher disease burden. Article Title
- Neutral Sentiment: Johnson & Johnson is drawing extra investor attention, likely reflecting renewed focus on the stock after the recent pipeline updates and broader interest in defensive healthcare names. Article Title
- Neutral Sentiment: Commentary on Johnson & Johnson as a potential high-growth dividend stock may be supporting the company’s income-investor appeal, but it does not appear to reflect a new operating development. Article Title
- Neutral Sentiment: Scotiabank reiterated a Buy rating on Johnson & Johnson, which can help reinforce confidence in the stock among investors. Article Title
Johnson & Johnson Trading Up 0.3%
Shares of Johnson & Johnson stock opened at $223.60 on Thursday. The company’s fifty day simple moving average is $232.25 and its 200-day simple moving average is $225.69. The company has a market cap of $538.25 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 2.18 and a beta of 0.26. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.4%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 61.97%.
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
